Mohamed A. Gouda

Oncology

1515 Holcombe Blvd
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

Tissue-Agnostic Cancer Therapy Approvals.

Tissue-Agnostic Cancer Therapy Approvals.

Journal: Hematology/oncology clinics of North America

Published: September 02, 2026

Liquid biopsy in oncology practice: A global survey by the Young Committee of the International Society of Liquid Biopsy (ISLB).

Liquid biopsy in oncology practice: A global survey by the Young Committee of the International Society of Liquid Biopsy (ISLB).

Journal: The journal of liquid biopsy

Published: June 19, 2026

Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.

Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors.

Journal: Journal for immunotherapy of cancer

Published: May 28, 2026

Autologous T Cell Antigen Coupler Targeting HER2 (TAC01-HER2) in Advanced or Metastatic Solid Tumors.

Autologous T Cell Antigen Coupler Targeting HER2 (TAC01-HER2) in Advanced or Metastatic Solid Tumors.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 05, 2026

Autologous T-cell antigen coupler targeting HER2 (TAC01-HER2) in advanced or metastatic solid tumors.

Autologous T-cell antigen coupler targeting HER2 (TAC01-HER2) in advanced or metastatic solid tumors.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 05, 2026

Tumor microenvironment changes after treatment with avelumab and immune-stimulating agent combinations in patients with advanced solid tumors.

Tumor microenvironment changes after treatment with avelumab and immune-stimulating agent combinations in patients with advanced solid tumors.

Journal: Research square

Published: February 06, 2026

Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumors.

Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumors.

Journal: Research square

Published: February 06, 2026

Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.

Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.

Journal: The oncologist

Published: September 30, 2025

Cancer in a drop: Advances in liquid biopsy in 2024.

Cancer in a drop: Advances in liquid biopsy in 2024.

Journal: Critical reviews in oncology/hematology

Published: March 10, 2025

Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors.

Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors.

Journal: ESMO open

Published: February 28, 2025

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer.

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer.

Journal: ESMO open

Published: February 06, 2025

Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.

Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.

Journal: JCO precision oncology

Published: February 06, 2025

Showing 1-12 of 69

Last Updated: 09/26/2026